Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their Commentary, Dr Pearson and colleagues1 presented a timely discussion of the ethics of research participation as a condition of coverage. We agree that this arrangement may be morally justified, as considerable uncertainty often exists for many years about the effectiveness and the safety of new therapies.2 Coverage with evidence development could become an important tool to reduce the abuse of emerging technologies while increasing knowledge about their true efficacy.3
Brezis M, Lehmann LS. Medicare Requirement for Research Participation. JAMA. 2006;296(24):2923–2925. doi:10.1001/jama.296.24.2924-a